



THE SIXTH ESWI  
**INFLUENZA**  
CONFERENCE  
10-13 SEPTEMBER 2017

**PROGRAMME**

[www.eswiconference.org](http://www.eswiconference.org)

*Organized by*  
**European**  
**Scientific**  
**Working group on**  
*Influenza*

## CONFERENCE PROGRAMME

SCIENTIFIC  
PROGRAMME

## SUNDAY 10 SEPTEMBER 2017

13:15-14:45	<b>SATELLITE SYMPOSIUM</b> <i>organized by the PREPARE consortium</i> <b>An integrated approach to understanding influenza</b> <span style="float: right;">OMEGA</span>
	<ul style="list-style-type: none"> <li>▪ <b>CHAIRS:</b> <b>Peter Openshaw</b> and <b>Menno de Jong</b></li> <li>1. Introduction to the PREPARE consortium, <b>Menno de Jong</b>, <i>University of Amsterdam, The Netherlands</i></li> <li>2. MOSAIC: a multicentre prospective study of severe influenza, <b>Long Hoang</b>, <i>Imperial College London, UK</i></li> <li>3. Influenza H1N1pdm infection of healthy volunteers, <b>Chris Chiu</b>, <i>Imperial College London, UK</i></li> <li>4. Transcriptomics in PREPARE, <b>Cosimo Cristella</b>, <i>University of Amsterdam, The Netherlands</i></li> <li>5. Is flu a disease of immune failure or excess, <b>Peter Openshaw</b>, <i>Imperial College London, UK</i></li> </ul>
15:00-16:30	<b>SATELLITE SYMPOSIUM</b> <i>supported by Vaccines Europe and ESWI</i> <b>EU manifesto on influenza vaccination</b> <span style="float: right;">OMEGA</span>
16:45-18:15	<b>SATELLITE SYMPOSIUM</b> <i>organized by ESPID and ESWI</i> <b>Should children be vaccinated against influenza?</b> <span style="float: right;">OMEGA</span>
	<ul style="list-style-type: none"> <li>▪ <b>CHAIR:</b> <b>Ab Osterhaus</b>, <i>ESWI chair</i></li> <li>1. The burden of disease in children, <b>Pieter Fraaij</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> <li>2. Influenza vaccines for children: how effective are they? <b>Ab Osterhaus</b>, <i>ESWI chair</i></li> <li>3. Universal vaccination of children: experiences from the UK, <b>Richard Pebody</b>, <i>Public Health England, UK</i></li> <li>4. Universal vaccination of children: the Finnish approach, <b>Terho Heikkinen</b>, <i>University of Turku, Finland</i></li> <li>5. Should children be routinely vaccinated against influenza and how can we foster the implementation of vaccination recommendations? Panel discussion and audience debate</li> </ul>
18:30-19:30	<b>OPENING CEREMONY</b> <span style="float: right;">OMEGA</span>
	<b>WELCOME AND OPENING:</b> <ul style="list-style-type: none"> <li>▪ <b>Ab Osterhaus</b>, <i>ESWI conference chair</i></li> </ul>
	<b>PLENARY ADDRESS:</b> <b>Influenza vaccination as a key public health tool</b> <ul style="list-style-type: none"> <li>▪ <b>Vytenis Andriukaitis</b>, <i>EU Commissioner Health and Food Safety</i></li> </ul>
	<b>KEYNOTE LECTURE:</b> <b>A universal influenza virus vaccine</b> <ul style="list-style-type: none"> <li>▪ <b>Peter Palese</b>, <i>Mount Sinai School of Medicine, USA</i></li> </ul>
19:30-22:00	<b>WELCOME RECEPTION</b> <span style="float: right;">MAIN CONFERENCE HALL</span>

**MONDAY 11 SEPTEMBER 2017**

08:30-10:00	<b>PL01 PLENARY SESSION</b> <span style="float: right;">OMEGA</span>	
	<b>KEYNOTE LECTURE:</b> <b>H5, H7 influenza viruses: where do we go?</b> ■ <b>Malik Peiris</b> , <i>University of Hongkong</i>	
	<b>Maternal immunization against influenza: benefits to mother and child</b> ■ <b>Marta Nunes</b> , <i>University of Witwatersrand, RSA</i>	
	<b>The use of influenza vaccines reduces antimicrobial resistance</b> ■ <b>Janet McElhaney</b> , <i>Northern Ontario School of Medicine, Canada</i>	
10:00-10:45	COFFEE BREAK	
10:15-10:45	<b>POSTER SESSION 1 Selection and introduction by Prof. Ab Osterhaus</b> <span style="float: right;">OMEGA</span>	
10:45-12:30	<b>PARALLEL SESSIONS</b> <span style="float: right;">OMEGA</span>	<span style="float: right;">ALFA</span>
	<b>SPA1 CLINICAL IMPACT AND DIAGNOSTIC APPROACHES</b>  ■ <b>CHAIR: Jianqing Xu</b> , <i>Fudan University Shanghai, PRC</i> ■ <b>CO-CHAIR: Cheryl Cohen</b> , <i>National Institute for Communicable Diseases, RSA</i>  1. The clinical impact of routine molecular point-of-care testing for respiratory viruses in hospitalised adults: results of a large pragmatic randomised controlled trial, <b>Tristan Clark</b> , <i>University of Southampton, UK</i>  2. In- and out-of-hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus in South Africa 2009-2013, <b>Cheryl Cohen</b> , <i>National Institute for Communicable Diseases, RSA</i>  3. A Novel Pharmacoeconomic Model to Compare Seasonal Influenza Vaccines in Italian Adults Aged 65 Years and Above, <b>Stefano Capri</b> , <i>Cattaneo-LIUC University, Italy</i>  4. Nasopharyngeal microbial signatures associated with severe influenza in children and in adults, <b>Laurence Josset</b> , <i>Hospices Civils de Lyon, France</i>	<b>SPB1 VIRUS STRUCTURE AND REPLICATION</b>  ■ <b>CHAIR: Stephen Cusack</b> , <i>EMBL Grenoble, France</i> ■ <b>CO-CHAIR: Rocío Coloma</b> , <i>Centro Nacional de Biotecnología, Madrid, Spain</i>  1. Analysis of the Higher Order RNA Structures Present Inside the Influenza A Virus Genome, <b>Bernadeta Dadonaite</b> , <i>University of Oxford, UK</i>  2. High-resolution mapping of Influenza A RNA packaging signals by MIME (Mutational Interference Mapping Experiment), <b>Maud Contrant</b> , <i>IBMC, France</i>  3. Structural insights into the mechanisms of influenza A virus RNA replication, <b>Haitian Fan</b> , <i>University of Oxford, UK</i>  4. Mechanistic single-molecule analysis of influenza virus replication, <b>Nicole Robb</b> , <i>University of Oxford, UK</i>
12:30-14:00	<b>LUNCH</b>	
	<b>SATELLITE SYMPOSIUM organized by SANOFI PASTEUR</b> <b>Influenza: changing the conversation</b> <span style="float: right;">OMEGA</span>	
	■ <b>CHAIR: Marc Van Ranst</b> , <i>University Hospitals of Leuven, Belgium</i>  1. Taking influenza seriously: individual and community impact of influenza, <b>Filipe Froes</b> , <i>Respiratory Medicine and Intensive Care Consultant, Lisbon, Portugal</i>  2. Influenza viruses are constantly evolving: the need for Quadrivalent influenza vaccines, <b>Marc Van Ranst</b> , <i>University Hospitals of Leuven, Belgium</i>  3. Developing a QIV: VaxigripTetra® clinical development, <b>Rosalind Hollingsworth</b> , <i>Global Medical Expert Lead, Influenza, Sanofi Pasteur, Swiftwater, USA</i>	

14:00-15:45	<b>PARALLEL SESSIONS</b> <span style="float: right;">OMEGA</span>	<span style="float: right;">ALFA</span>
	<b>SPA2 EPIDEMICS AND PANDEMIC THREATS</b> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Yoshihiro Kawaoka</b>, <i>University of Wisconsin, USA</i></li> <li>▪ <b>CO-CHAIR: Peng Wu</b>, <i>University of Hong Kong, Hong Kong SAR</i></li> </ul> <ol style="list-style-type: none"> <li>1. Identification of H1N1 influenza virus survival determinants: amino-acids on the HA protein modulate the stability of viruses in the environment, <b>Thomas Labadie</b>, <i>Institut Pasteur, France</i></li> <li>2. Evaluation of potential risk of transmission of Avian Influenza A at the human-animal interface in response to unusual crow die off in Bangladesh, <b>Mahbubur Rahman</b>, <i>Institute of Epidemiology, Disease Control and Research, Bangladesh</i></li> <li>3. Outbreak of highly pathogenic avian influenza A virus H5N1 among poultry in Ghana, <b>Ivy Assante</b>, <i>Heinrich-Pette-Institute, Germany</i></li> <li>4. Influenza-associated mortality in Yancheng, China, 2011-2015, <b>Qian Xiong</b>, <i>University of Hong Kong, Hong Kong SAR</i></li> </ol>	<b>SPB2 VIRAL FACTORS IN PATHOGENESIS</b> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Adolfo Garcia-Sastre</b>, <i>Mount Sinai School of Medicine, USA</i></li> <li>▪ <b>CO-CHAIR: Michelle Tate</b>, <i>University of Melbourne, Australia</i></li> </ul> <ol style="list-style-type: none"> <li>1. Factors determining the optimum pH stability for pathogenicity and transmissibility of human influenza viruses, <b>Anika Singanayagam</b>, <i>Imperial College London, UK</i></li> <li>2. Variable pathogenicity of H7N7 recombinant viruses in chickens, turkeys and ducks, <b>David Scheibner</b>, <i>Friedrich-Loeffler Institut, Germany</i></li> <li>3. Avian-origin PB1 Segment of Influenza A Virus Confers a Parallel Selective Advantage towards Virus Adaptation and Pandemic Formation, <b>Yan Zhou</b>, <i>University of Saskatchewan, Canada</i></li> <li>4. Functional analysis of the influenza A virus M2 protein interaction with Na,K-ATPase in influenza pneumonia, <b>Jessica Schulze</b>, <i>Robert Koch Institute, Germany</i></li> </ol>
15:45-16:15	<b>COFFEE BREAK</b>	
16:15-18:00	<b>PARALLEL SESSIONS</b> <span style="float: right;">OMEGA</span>	<span style="float: right;">ALFA</span>
	<b>SPA3 IMMUNOLOGY</b> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Rafi Ahmed</b>, <i>Emory University, USA</i></li> <li>▪ <b>CO-CHAIR: Rory Dylan de Vries</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> </ul> <ol style="list-style-type: none"> <li>1. First identification of cross-reactive CD8+ T cell immunity across influenza A, B and C viruses, <b>Marios Koutsakos</b>, <i>University of Melbourne, Australia</i></li> <li>2. Engaging naive vs. memory B cells in humans: Lessons from H5N1 vaccination, <b>Ali Ellebedy</b>, <i>Emory University, USA</i></li> <li>3. Extra-epitopic amino acids influence recognition of the 2009 H1N1 pandemic influenza A virus by CD8+ T cells specific for the conserved M158-66 epitope, <b>Carolien van de Sandt</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> <li>4. Constitutive TRIM22 expression confers intrinsic antiviral immunity in the respiratory tract, <b>Edward Hutchinson</b>, <i>University of Glasgow, UK</i></li> </ol>	<b>SPB3 MATHEMATICAL MODELING</b> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Colin Russell</b>, <i>Cambridge University, UK</i></li> <li>▪ <b>CO-CHAIR: Katelyn Gostic</b>, <i>University of California, USA</i></li> </ul> <ol style="list-style-type: none"> <li>1. Population dynamics constrain immune escape in human influenza A, <b>Dylan Morris</b>, <i>Princeton University, USA</i></li> <li>2. Estimates of Annual and Average Global Seasonal Influenza-associated Respiratory Mortality from 1999-2015, <b>Angela Iuliano</b>, <i>Centers for Disease Control and Prevention, USA</i></li> <li>3. Failing to account for pre-existing immunity against influenza strains leads to an underestimation of influenza vaccine efficacy, <b>Pascal Crépey</b>, <i>Ecole des Hautes Etudes en Santé Publique, France</i></li> <li>4. Should we expect broadly protective immunity and childhood hemagglutinin imprinting to impact seasonal influenza epidemiology? <b>Katelyn Gostic</b>, <i>University of California, USA</i></li> </ol>
18:00-19:30	<b>PRIVATE SATELLITE SYMPOSIUM</b> <span style="float: right;">OMEGA</span>	

## TUESDAY 12 SEPTEMBER 2017

08:00-09:00	<b>SATELLITE SYMPOSIUM COMPANY LECTURES</b> <span style="float: right;">OMEGA</span>	
08:00-08:20	<b>Influenza Hub: Raising awareness about influenza prevention by using social media and innovative engagement techniques</b> <ul style="list-style-type: none"> <li>▪ <b>Philip Weiss</b>, <i>ZN Consulting and Bram Palache</i>, <i>FluPal Consultancy B.V.</i></li> </ul>	
08:20-08:40	<b>Treatment of Influenza and RSV –Janssen’s Pipeline in Respiratory Infections</b> <ul style="list-style-type: none"> <li>▪ <b>Jim Witek</b>, <i>Global Franchise Medical Leader, Respiratory Infectious Diseases, Janssen</i></li> </ul>	
08:40-09:00	<b>Update on the Clinical Development of Plant-Made Quadrivalent Influenza VLP Vaccine</b> <ul style="list-style-type: none"> <li>▪ <b>Brian J. Ward</b>, <i>Medical Officer for Medicago</i></li> </ul>	
09:00-10:00	<b>PL02 PLENARY SESSION</b> <span style="float: right;">OMEGA</span>	
	<b>KEYNOTE LECTURES:</b> <b>Clinical management of influenza: where do we go?</b> <ul style="list-style-type: none"> <li>▪ <b>Jonathan Van-Tam</b>, <i>University of Nottingham, UK</i></li> </ul>	
	<b>Protective and pathological roles of coagulation proteases and PARs in influenza infection</b> <ul style="list-style-type: none"> <li>▪ <b>Nigel Mackman</b>, <i>University of North Carolina at Chapel Hill</i></li> </ul>	
10:00-10:45	COFFEE BREAK	
10:15-10:45	POSTER SESSION 2 Selection and introduction by Dr. Edward Hutchinson <span style="float: right;">OMEGA</span>	
10:45-12:30	<b>PARALLEL SESSIONS</b> <span style="float: right;">OMEGA</span>	<b>ALFA</b>
	<b>SPA4 ANTIVIRALS AND RESISTANCE/ MONOCLONAL ANTIBODY THERAPIES</b> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Elena Govorkova</b>, <i>St. Jude Children’s Research Hospital, USA</i></li> <li>▪ <b>CO-CHAIR: Florian Krammer</b> <i>Mount Sinai School of Medicine, USA</i></li> </ul> <ol style="list-style-type: none"> <li>1. Mechanisms of protection of monoclonal anti-influenza B neuraminidase IgG, IgM and IgA antibodies in a murine challenge model, <b>Veronika Chromikova</b>, <i>Mount Sinai School of Medicine, USA</i></li> <li>2. A Host-Directed Antiviral Approach for Treatment of Influenza Virus Infections, <b>Kelly Warfield</b>, <i>Emergent Biosolutions, USA</i></li> <li>3. Impact of in-hospital neuraminidase inhibitor treatment on length of stay: an Individual Participant Data Meta-analysis, <b>Sudhir Venkatesan</b>, <i>University of Nottingham, UK</i></li> <li>4. Resistance analyses in subjects treated with pimodivir (jnj-63623872): results from the phase 2b topaz trial in acute uncomplicated seasonal influenza, <b>Johan Vingerhoets</b>, <i>Janssen, Belgium</i></li> </ol>	<b>SPB4 ANIMAL FLU-ECOLOGY AND EPIDEMIOLOGY OF ANIMAL INFLUENZA</b> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Gavin Smith</b>, <i>Duke-NUS, Singapore</i></li> <li>▪ <b>CO-CHAIR: Josanne Verhagen</b>, <i>Linnaeus University Växjö, Sweden</i></li> </ul> <ol style="list-style-type: none"> <li>1. Swarm incursions during winter 2016/17 of multiple reassortants of highly pathogenic avian H5N8 influenza strains causing the largest epizootic in birds ever recorded in Germany, <b>Martin Beer</b>, <i>Friedrich Löffler Institut, Germany</i></li> <li>2. Circulation, prevalence and genetic analyses of wild bird avian influenza viruses in a key active surveillance site in Eurasia: 2010-2017, <b>Nicola Lewis</b>, <i>APHA Virology, UK</i></li> <li>3. Circulation of low and highly pathogenic avian influenza A viruses among wild and domestic birds in Ukraine, <b>Denys Muzyka</b>, <i>National Scientific Center Institute of Experimental and Clinical Veterinary Medicine, Ukraine</i></li> <li>4. Mobile poultry vendors in Bangladesh: practices and movement patterns, <b>Ausraful Islam</b>, <i>ICDDR, Bangladesh</i></li> </ol>

12:30-14:00	LUNCH	
<p><b>SATELLITE SYMPOSIUM</b> <i>organized by SEQIRUS</i>  <b>Seasonal Influenza in Older Adults: Addressing the challenges and understanding immunization options</b> <span style="float: right;">OMEGA</span></p>		
<ol style="list-style-type: none"> <li>1. <b>Dr. George Kassianos</b>, <i>President British Global &amp; Travel Health Association and National Immunisation Lead Royal College of General Practitioners</i></li> <li>2. <b>Dr. Paul Van Buynder</b>, <i>Professor, Griffith University and Chairman, Immunisation Coalition</i></li> <li>3. <b>Dr. Adolfo García-Sastre</b>, <i>Professor, Icahn School of Medicine at Mount Sinai and Director, Global Health and Emerging Pathogens Institute</i></li> <li>4. <b>Prof. Marco Barbieri</b>, <i>Honorary Research Fellow, Centre for Health Economics, University of York</i></li> </ol>		
14:00-15:45	<p><b>PARALLEL SESSIONS</b> <span style="float: right;">OMEGA</span></p>	<p><b>ALFA</b></p>
<p><b>SPAS VACCINES: CURRENT AND NOVEL APPROACHES</b></p>		<p><b>SPBS GENETICS AND EVOLUTION OF VIRUS AND HOST</b></p>
<ul style="list-style-type: none"> <li>▪ <b>CHAIR: Guus Rimmelzwaan</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> <li>▪ <b>CO-CHAIR: Ali Ellebedy</b>, <i>Emory University, USA</i></li> </ul> <ol style="list-style-type: none"> <li>1. Nucleoside-modified mRNA vaccination induces influenza virus hemagglutinin stalk-specific antibody responses, <b>Norbert Pardi</b>, <i>University of Pennsylvania, USA</i></li> <li>2. Adjuvanted mini-HA induces broadly neutralizing antibodies in pre-exposed non-human primates which protect mice from lethal influenza challenge, <b>Börries Brandenburg</b>, <i>Janssen, The Netherlands</i></li> <li>3. Influenza virus hemagglutinin stalk-specific antibodies in human sera measured by ELISA correlate with in vivo protection in a mouse serum transfer model, <b>Raffael Nachbagauer</b>, <i>Mount Sinai School of Medicine, USA</i></li> <li>4. Pre-existing orthopoxvirus-specific immunity interferes with t cell responses induced by vaccination with recombinant modified vaccinia virus ankara in mice, <b>Rory de Vries</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> </ol>		<ul style="list-style-type: none"> <li>▪ <b>CHAIR: Ron Fouchier</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> <li>▪ <b>CO-CHAIR: Craig Thompson</b>, <i>University of Oxford, UK</i></li> </ul> <ol style="list-style-type: none"> <li>1. Avian influenza A/H10N7 virus outbreak in seals: identification and characterization of mutations and associated phenotypes driving airborne transmission between ferrets, <b>Sander Herfst</b>, <i>Erasmus MC, The Netherlands</i></li> <li>2. Characterization of a newly emerged variant of H7N9 virus containing a polybasic motif in the hemagglutinin protein, <b>Honglin Chen</b>, <i>University of Hong Kong, Hong Kong SAR</i></li> <li>3. Polymerase enhancing substitutions that arise during infection with highly pathogenic avian H5N1 influenza in humans, <b>Dirk Eggink</b>, <i>Academic Medical Center Amsterdam, The Netherlands</i></li> <li>4. Influenza virus quasispecies characterization of serial upper and lower respiratory tract samples from mechanically ventilated patients, <b>Björn Koel</b>, <i>Academic Medical Center Amsterdam, The Netherlands</i></li> </ol>
15:45-16:15	COFFEE BREAK	

16:15-18:00	<b>PARALLEL SESSIONS</b> <span style="float: right;">OMEGA</span>	<span style="float: right;">ALFA</span>
	<p><b>SPB6 EVALUATION OF VACCINE SAFETY AND EFFECTIVENESS</b></p> <p><b>CHAIR:</b> <b>Maryna Eichelberger</b>, <i>Food and Drug Administration, USA</i>  <b>CO-CHAIR:</b> <b>Katja Höschler</b>, <i>Public Health England, UK</i></p> <ol style="list-style-type: none"> <li>1. Efficacy immunogenicity and safety study of a 0.5 ml dose of a quadrivalent inactivated influenza vaccine in children from 6 to 35 months, <b>Stephanie Pepin</b>, <i>Sanofi Pasteur, France</i></li> <li>2. Assessment of the effect of repeated vaccination on current season influenza vaccine effectiveness (IVE) in patients 60 years old or over, seasons 2013-2014 to 2015-2016 in the Valencia Region, <b>Victor Baselga-Moreno</b>, <i>FISABIO, Spain</i></li> <li>3. A new hospital surveillance system in Norway for severe influenza in children, <b>Håkon Bøås</b>, <i>Institute of Public Health, Norway</i></li> <li>4. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine, versus separate administration, in ≥50-year-old adults: results from phase III, randomized, non-inferiority trial, <b>Geert Leroux-Roels</b>, <i>University of Ghent, Belgium</i></li> </ol>	<p><b>SPB6 RISK MANAGEMENT AND MITIGATION OF EPIDEMIC AND PANDEMIC THREATS</b></p> <p>■ <b>CHAIR:</b> <b>Marie-Paule Kieny</b>, <i>World Health Organization</i>  ■ <b>CO-CHAIR:</b> <b>Irina Isakova-Sivak</b>, <i>Institute of Experimental Medicine Saint Petersburg, Russia</i></p> <ol style="list-style-type: none"> <li>1. Effect of a reinforced hospital campaign for seasonal influenza vaccination of healthcare workers 2016-2017 on nosocomial outbreaks in the University Hospital of Lyon, France, <b>Bruno Lina</b>, <i>University of Lyon, France</i></li> <li>2. Partnership for Influenza Vaccine Introduction: early progress in catalyzing influenza vaccine use in low and middle-income countries, <b>Joseph S. Bresee</b>, <i>Centers for Disease Control and Prevention, USA</i></li> <li>3. Outbreaks of highly pathogenic avian influenza A(H5N5) and A(H5N8) virus infection in birds: National risk assessments and protective measures for humans in 22 EU/EEA countries, 2016/17, <b>Cornelia Adlhoc</b>, <i>European Centre for Disease Prevention and Control, Sweden</i></li> <li>4. 2016/17 Seasonal Influenza Vaccine Uptake by Medical Students in the UK, <b>Rachel Groome</b>, <i>University of Nottingham, UK</i></li> </ol>
18:00-19:30	<b>SATELLITE SYMPOSIUM organized by MUGAS Foundation</b> <b>NEXT GENERATION INFLUENZA VACCINES: THE FUTURE OF INFLUENZA IMMUNIZATION</b> <span style="float: right;">OMEGA</span>	
	<p>■ <b>CHAIR:</b> <b>Ab Osterhaus</b>, <i>ESWI chair and MUGAS co-founder</i></p> <ol style="list-style-type: none"> <li>1. The need for improved influenza vaccines and adjuvants, <b>Ab Osterhaus</b>, <i>ESWI chair and MUGAS co-founder</i></li> <li>2. Molecular basis of strain variation, <b>Ron Fouchier</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> <li>3. Pre-emptive vaccine updates and immunity management, <b>Derek Smith</b>, <i>Cambridge University, UK</i></li> <li>4. Mammalian Cell Culture and the Evolution of the Influenza Vaccine System, <b>Ethan C. Settembre</b>, <i>Seqirus, Cambridge, MA, USA</i></li> <li>5. The plant-based Proficia™ technology, a rapid and efficient platform for the production of influenza VLP vaccines, <b>Nathalie Charland</b>, <i>Senior Director, Scientific &amp; Medical Affairs for Medicago</i></li> <li>6. Influenza adjuvanted surface low-dose Grippol® Quadrivalent vaccine immunogenicity, safety and efficacy, <b>Marina Abramova</b>, <i>Vice President, NPO Petrovax Pharm</i></li> <li>7. The revolution in influenza vaccine manufacturing: The B.E.S.T. platform used to produce Flublok®, <b>Manon Cox</b>, <i>President and CEO, Protein Sciences</i></li> </ol>	
20:00-22:00	<b>FAREWELL DINNER</b> <span style="float: right;">LATVIA SOCIETY HOUSE</span>	

## WEDNESDAY 13 SEPTEMBER 2017

08:00-09:15	<b>PL04 YOUNG SCIENTISTS PLENARY SESSION</b> <span style="float: right;">OMEGA</span>	
	<ul style="list-style-type: none"> <li>■ <b>CHAIR: Ed Hutchinson</b>, <i>University of Glasgow, UK</i></li> <li>■ <b>CO-CHAIR: Claude Hannoun</b>, <i>Institut Pasteur Paris, France</i></li> </ul> <p><b>speakers:</b></p> <ol style="list-style-type: none"> <li>1. <b>Debby van Riel</b>, <i>ESWI Best Body of Work award winner 2017</i></li> <li>2. <b>Matthew S. Miller</b>, <i>Best Oral Presentation ESWI 2014</i></li> <li>3. <b>Steven F. Baker</b>, <i>Best Poster Presentation ESWI 2014</i></li> <li>4. <b>Karen Laurie</b>, <i>Award Winner Orthomyxovirus Research Conference 2015</i></li> <li>5. <b>Jason Long</b>, <i>Award Winner Orthomyxovirus Research Conference 2015</i></li> </ol>	
09:15-10:00	COFFEE BREAK	
09:30-10:00	<b>POSTER SESSION 3 Selection and introduction by by Prof. Gülsah Gabriel</b> <span style="float: right;">OMEGA</span>	
10:00-11:45	<b>PARALLEL SESSIONS</b> <span style="float: right;">OMEGA</span>	<b>ALFA</b>
	<b>SPA7 MATERNAL AND CHILDHOOD IMMUNIZATION</b>	<b>SPB7 HOST FACTORS IN PATHOGENESIS</b>
	<ul style="list-style-type: none"> <li>■ <b>CHAIR: Terho Heikkinen</b>, <i>University of Turku, Finland</i></li> <li>■ <b>CO-CHAIR: Marta Nunes</b>, <i>University of Witwatersrand, RSA</i></li> </ul> <ol style="list-style-type: none"> <li>1. Seroprevalence of seasonal influenza virus infection among unvaccinated pregnant women in Bangladesh, 2013-2014, <b>Zubair Akhtar</b>, <i>ICDDR, Bangladesh</i></li> <li>2. Influenza A virus infection during pregnancy: high progesterone levels during pregnancy increase mortality in pregnant influenza infected mice by impairing the anti-viral immune response, <b>Alexandra Hierweger</b>, <i>University Medical Center Hamburg-Eppendorf, Germany</i></li> <li>3. A randomised controlled trial to increase influenza vaccine uptake in children aged from 6 to 24 months, <b>Karene Yeung</b>, <i>The Chinese University of Hongkong, Hong Kong SAR</i></li> <li>4. Assessing direct and indirect effects of pediatric influenza vaccination in Germany using individual-based simulations – Epidemiological considerations, <b>Ruprecht Schmidt-Ott</b>, <i>GlaxoSmithKline, Germany</i></li> </ol>	<ul style="list-style-type: none"> <li>■ <b>CHAIR: Gülsah Gabriel</b>, <i>Heinrich Pette Institute Hamburg, Germany</i></li> <li>■ <b>CO-CHAIR: Ivan Marazzi</b>, <i>Mount Sinai School of Medicine, USA</i></li> </ul> <ol style="list-style-type: none"> <li>1. Emergence of Highly Virulent H1N1 Influenza Virus Strains in Allogeneically Pregnant Mice, <b>Stephanie Bertram</b>, <i>Heinrich Pette Institute, Germany</i></li> <li>2. SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses, <b>Alexandra Dudek</b>, <i>Institute of Virology Freiburg, Germany</i></li> <li>3. Resistance to influenza A infections in mice carrying deletions in host protease genes, <b>Klaus Schughart</b>, <i>Helmholtz Centre for Infection Research, Germany</i></li> <li>4. The role of obesity in the generation of influenza virus quasispecies, <b>Kirsty Short</b>, <i>University of Queensland, Australia</i></li> </ol>
11:45-12:15	COFFEE BREAK	



12:15-13:45

## PLOS PLENARY SESSION - LATE BREAKERS

OMEGA

- **CHAIR: Sylvie van der Werf**, *Institut Pasteur Paris, France*
  - **CO-CHAIR: Susanne Herold**, *University of Giessen, Germany*
1. Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza in Otherwise Healthy Adolescents and Adults with Seasonal Influenza, **Frederick Hayden**, *University of Virginia School of Medicine, Charlottesville, Virginia, USA*
  2. The OPAL Trial: A Placebo-controlled Trial Studying Pimodivir (Formerly JNJ-63623872 or VX-787) plus Oseltamivir vs. Placebo plus Oseltamivir in Adult and Elderly Hospitalized Patients with Influenza A Infection, **Brian O'Neil**, *Wayne State University School of Medicine, United States of America*
  3. Targeting the pro-viral host factor, focal adhesion kinase (FAK), limits influenza A virus infections and NFκB regulated pro-inflammatory responses in vivo and in vitro, **Silke Bergmann**, *Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America*
  4. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials, **Arnold S Monto**, *University of Michigan School of Public Health, United States of America*

## CLOSING CEREMONY

OMEGA

13:45-14:30

LUNCH

**SUNDAY 10 SEPTEMBER 2017**

13:15-14:45	<b>SATELLITE SYMPOSIUM</b> <i>organized by the PREPARE consortium</i> <b>An integrated approach to understanding influenza</b> <div style="text-align: right;"><b>OMEGA</b></div>
	<ul style="list-style-type: none"> <li>▪ <b>CHAIRS:</b> <b>Peter Openshaw</b> and <b>Menno de Jong</b></li> <li>1. Introduction to the PREPARE consortium, <b>Menno de Jong</b>, <i>University of Amsterdam, The Netherlands</i></li> <li>2. MOSAIC: a multicentre prospective study of severe influenza, <b>Long Hoang</b>, <i>Imperial College London, UK</i></li> <li>3. Influenza H1N1pdm infection of healthy volunteers, <b>Chris Chiu</b>, <i>Imperial College London, UK</i></li> <li>4. Transcriptomics in PREPARE, <b>Cosimo Cristella</b>, <i>University of Amsterdam, The Netherlands</i></li> <li>5. Is flu a disease of immune failure or excess, <b>Peter Openshaw</b>, <i>Imperial College London, UK</i></li> </ul>
15:00-16:30	<b>SATELLITE SYMPOSIUM</b> <i>supported by Vaccines Europe and ESWI</i> <b>EU manifesto on influenza vaccination</b> <div style="text-align: right;"><b>OMEGA</b></div>
16:45-18:15	<b>SATELLITE SYMPOSIUM</b> <i>organized by ESPID and ESWI</i> <b>Should children be vaccinated against influenza?</b> <div style="text-align: right;"><b>OMEGA</b></div>
	<ul style="list-style-type: none"> <li>▪ <b>CHAIR:</b> <b>Ab Osterhaus</b>, <i>ESWI chair</i></li> <li>1. The burden of disease in children, <b>Pieter Fraaij</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> <li>2. Influenza vaccines for children: how effective are they? <b>Ab Osterhaus</b>, <i>ESWI chair</i></li> <li>3. Universal vaccination of children: experiences from the UK, <b>Richard Pebody</b>, <i>Public Health England, UK</i></li> <li>4. Universal vaccination of children: the Finnish approach, <b>Terho Heikkinen</b>, <i>University of Turku, Finland</i></li> <li>5. Should children be routinely vaccinated against influenza and how can we foster the implementation of vaccination recommendations? Panel discussion and audience debate</li> </ul>
18:30-19:30	<b>OPENING CEREMONY</b> <div style="text-align: right;"><b>OMEGA</b></div> <p><b>WELCOME AND OPENING:</b></p> <ul style="list-style-type: none"> <li>▪ <b>Ab Osterhaus</b>, <i>ESWI conference chair</i></li> </ul> <p><b>PLENARY ADDRESS:</b></p> <p><b>Influenza vaccination as a key public health tool</b></p> <ul style="list-style-type: none"> <li>▪ <b>Vytenis Andriukaitis</b>, <i>EU Commissioner Health and Food Safety</i></li> </ul> <p><b>KEYNOTE LECTURE:</b></p> <p><b>A universal influenza virus vaccine</b></p> <ul style="list-style-type: none"> <li>▪ <b>Peter Palese</b>, <i>Mount Sinai School of Medicine, USA</i></li> </ul>
19:30-22:00	<b>WELCOME RECEPTION</b> <div style="text-align: right;"><b>MAIN CONFERENCE HALL</b></div>

## MONDAY 11 SEPTEMBER 2017

08:30-10:00	<b>PL01 PLENARY SESSION</b> <span style="float: right;">OMEGA</span> <p><b>KEYNOTE LECTURE:</b>  <b>H5, H7 influenza viruses: where do we go?</b></p> <ul style="list-style-type: none"> <li>▪ <b>Malik Peiris</b>, <i>University of Hongkong</i></li> </ul> <p><b>Maternal immunization against influenza: benefits to mother and child</b></p> <ul style="list-style-type: none"> <li>▪ <b>Marta Nunes</b>, <i>University of Witwatersrand, RSA</i></li> </ul> <p><b>The use of influenza vaccines reduces antimicrobial resistance</b></p> <ul style="list-style-type: none"> <li>▪ <b>Janet McElhaney</b>, <i>Northern Ontario School of Medicine, Canada</i></li> </ul>
10:00-10:45	COFFEE BREAK
10:15-10:45	<b>POSTER SESSION 1 Selection and introduction by Prof. Ab Osterhaus</b> <span style="float: right;">OMEGA</span>
10:45-12:30	<b>SP11 ALL YOU NEED TO KNOW ABOUT INFLUENZA VIRUSES</b> <span style="float: right;">BETA</span> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Ab Osterhaus</b>, <i>RIZ Hannover, Germany</i></li> </ul> <ol style="list-style-type: none"> <li>1. All you need to know about influenza viruses, <b>Ab Osterhaus</b>, <i>RIZ Tiho Hannover, Germany</i></li> <li>2. Close focus: vaccines and antivirals, <b>Florian Krammer</b>, <i>Mount Sinai School of Medicine, USA</i></li> <li>3. How flu viruses travel around the world, <b>Colin Russell</b>, <i>University of Cambridge, UK</i></li> <li>4. Who is at risk of flu infections and are these risk groups well-protected? ECDC informs, <b>Pasi Penttinen</b>, <i>ECDC</i></li> <li>5. The economic impact of flu: WHO informs, <b>Caroline Brown</b>, <i>WHO Europe</i></li> </ol>
12:30-14:00	<b>LUNCH</b> <p><b>SATELLITE SYMPOSIUM organized by SANOFI PASTEUR</b>  <b>Influenza: changing the conversation</b> <span style="float: right;">OMEGA</span></p> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Marc Van Ranst</b>, <i>University Hospitals of Leuven, Belgium</i></li> </ul> <ol style="list-style-type: none"> <li>1. Taking influenza seriously: individual and community impact of influenza, <b>Filipe Froes</b>, <i>Respiratory Medicine and Intensive Care Consultant, Lisbon, Portugal</i></li> <li>2. Influenza viruses are constantly evolving: the need for Quadrivalent influenza vaccines, <b>Marc Van Ranst</b>, <i>University Hospitals of Leuven, Belgium</i></li> <li>3. Developing a QIV: VaxigripTetra® clinical development, <b>Rosalind Hollingsworth</b>, <i>Global Medical Expert Lead, Influenza, Sanofi Pasteur, Swiftwater, USA</i></li> </ol>
14:00-15:45	<b>SP12 PREVENTION AND TREATMENT OF INFLUENZA</b> <span style="float: right;">BETA</span> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Jonathan Van-Tam</b>, <i>University of Nottingham, UK</i></li> </ul> <ol style="list-style-type: none"> <li>1. Vaccines: current and novel approaches, <b>Guus Rimmelzwaan</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> <li>2. Effectiveness of seasonal and pandemic influenza vaccines, <b>Jonathan Van-Tam</b>, <i>University of Nottingham, UK</i></li> <li>3. Safety of seasonal and pandemic influenza vaccines, <b>Michael McNeil</b>, <i>CDC Immunization Safety Office, USA</i></li> <li>4. Antiviral medicines against influenza: current and novel approaches, <b>Lieve Naesens</b>, <i>Rega Institute KU Leuven, Belgium</i></li> <li>5. Safety and effectiveness of influenza antivirals, <b>Nicole Bouvier</b>, <i>Mount Sinai School of Medicine, USA</i></li> </ol>
15:45-16:15	COFFEE BREAK
16:15-18:00	<b>SP13 ADDRESSING INFLUENZA IN PRACTICE: WHO'S INVOLVED?</b> <span style="float: right;">BETA</span> <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Susanne Herold</b>, <i>University of Giessen, Germany</i></li> </ul> <ol style="list-style-type: none"> <li>1. Family doctors: our trusted advisors, <b>Ted van Essen</b>, <i>general practitioner, The Netherlands</i></li> <li>2. Protecting healthcare workers and patients in hospital settings, <b>Roman Prymula</b>, <i>University Hospital Hradec Kralove, Czech Republic</i></li> <li>3. Nurses and midwives: in the forefront in the fight against flu, <b>Agita Melbārde-Kelme</b>, <i>European Forum of National Nursing and Midwifery Associations (EFNNMA), Latvia</i></li> <li>4. The new role of pharmacists in flu prevention, <b>Isabel Jacinto</b>, <i>National Association of Pharmacies, Portugal</i></li> <li>5. Respiratory physicians tackling influenza, <b>Susanne Herold</b>, <i>University of Giessen, Germany</i></li> </ol>
18:00-19:30	<b>PRIVATE SATELLITE SYMPOSIUM</b> <span style="float: right;">OMEGA</span>

## TUESDAY 12 SEPTEMBER 2017

08:00-09:00	<b>SATELLITE SYMPOSIUM COMPANY LECTURES</b> <span style="float: right;">OMEGA</span>
08:00-08:20	<b>Influenza Hub: Raising awareness about influenza prevention by using social media and innovative engagement techniques</b> <ul style="list-style-type: none"> <li>▪ <b>Philip Weiss</b>, ZN Consulting and <b>Bram Palache</b>, FluPal Consultancy B.V.</li> </ul>
08:20-08:40	<b>Treatment of Influenza and RSV –Janssen’s Pipeline in Respiratory Infections</b> <ul style="list-style-type: none"> <li>▪ <b>Jim Witek</b>, Global Franchise Medical Leader, Respiratory Infectious Diseases, Janssen</li> </ul>
08:40-09:00	<b>Update on the Clinical Development of Plant-Made Quadrivalent Influenza VLP Vaccine</b> <ul style="list-style-type: none"> <li>▪ <b>Brian J. Ward</b>, Medical Officer for Medicago</li> </ul>
09:00-10:00	<b>PL02 PLENARY SESSION</b> <span style="float: right;">OMEGA</span>  <b>KEYNOTE LECTURES:</b> <b>Clinical management of influenza: where do we go?</b> <ul style="list-style-type: none"> <li>▪ <b>Jonathan Van-Tam</b>, University of Nottingham, UK</li> </ul> <b>Protective and pathological roles of coagulation proteases and PARs in influenza infection</b> <ul style="list-style-type: none"> <li>▪ <b>Nigel Mackman</b>, University of North Carolina at Chapel Hill</li> </ul>
10:00-10:45	COFFEE BREAK
10:15-10:45	<b>POSTER SESSION 2</b> Selection and introduction by Dr. Edward Hutchinson <span style="float: right;">OMEGA</span>
10:45-12:30	<b>SPI4 IMPLEMENTATION OF VACCINATION POLICIES: SUCCESS STORIES AND HURDLES</b> <span style="float: right;">BETA</span>  <ul style="list-style-type: none"> <li>▪ <b>CHAIR: Peter Openshaw</b>, Imperial College London, UK</li> <li>1. How does NHS England manage to achieve one of the highest seasonal Influenza vaccination rates in Europe? <b>George Kassianos</b>, Immunisation Lead for the Royal College of General Practitioners, UK</li> <li>2. Influenza vaccination in Mexico, <b>Jose Angel Cordova Villalobos</b>, Mexico, former Minister of Health (2006 - 2011)</li> <li>3. The role of ‘experts’ in guiding policy: the immunologist’s perspective, <b>Peter Openshaw</b>, Imperial College London, UK</li> <li>4. A journalist’s opinion on vaccination policies and the role of scientists, <b>Debora McKenzie</b>, New Scientist Magazine</li> <li>5. The Full Economic Contributions of Older Adults: Implications for Influenza Vaccination, <b>Alexander Khoury</b>, Harvard Chan School of Public Health, US</li> </ul>
12:30-14:00	LUNCH
	<b>SATELLITE SYMPOSIUM</b> <i>organized by SEQIRUS</i> <b>Seasonal Influenza in Older Adults: Addressing the challenges and understanding immunization options</b> <span style="float: right;">OMEGA</span>  <ol style="list-style-type: none"> <li>1. <b>Dr. George Kassianos</b>, President British Global &amp; Travel Health Association and National Immunisation Lead Royal College of General Practitioners</li> <li>2. <b>Dr. Paul Van Buynder</b>, Professor, Griffith University and Chairman, Immunisation Coalition</li> <li>3. <b>Dr. Adolfo Garcia-Sastre</b>, Professor, Icahn School of Medicine at Mount Sinai and Director, Global Health and Emerging Pathogens Institute</li> <li>4. <b>Prof. Marco Barbieri</b>, Honorary Research Fellow, Centre for Health Economics, University of York</li> </ol>

14:00-15:45	<p><b>SPI5 INFLUENZA PREPAREDNESS: WHAT CAN WE LEARN FROM OTHER VIRUS OUTBREAKS?</b> <span style="float: right;">BETA</span></p> <p>■ <b>CHAIR: Marc Van Ranst</b>, <i>University of Leuven, Belgium</i></p> <ol style="list-style-type: none"> <li>1. Ebola: what went wrong and where do we go now? <b>Guido van der Groen</b>, <i>Prof. Em. Institute for Tropical Medicine in Antwerp, Belgium</i></li> <li>2. How to successfully prevent a major disease outbreak: from SARS to MERS, <b>Ab Osterhaus</b>, <i>RIZ Tiho Hannover, Germany</i></li> <li>3. Zika virus as a global public health emergency, <b>Herve Zeller</b>, <i>head of disease programme for Emerging and vector-borne diseases, ECDC</i></li> <li>4. The H1N1 health crisis: how did we cope and are we prepared for a new outbreak? <b>Marc Van Ranst</b>, <i>University of Leuven, Belgium</i></li> <li>5. Revised pandemic preparedness plans and global update on PIP Framework, <b>Wenqing Zhang</b>, <i>Global Influenza Programme, World Health Organization, Switzerland</i></li> </ol>
15:45-16:15	COFFEE BREAK
16:15-18:00	<p><b>SPI6 REACHING OUT TO PEOPLE AT RISK</b> <span style="float: right;">BETA</span></p> <p>■ <b>CHAIR: Litjen Tan</b>, <i>Immunization Action Coalition, USA</i></p> <ol style="list-style-type: none"> <li>1. Should children be vaccinated against influenza? <b>Adam Finn</b>, <i>University of Bristol, UK and president ESPID</i></li> <li>2. Should travellers be vaccinated against flu? <b>Marco Goeijenbier</b>, <i>Harbour Hospital Rotterdam, The Netherlands</i></li> <li>3. Protecting diabetes patients against flu, <b>Perry van Genderen</b>, <i>Harbour Hospital Rotterdam, The Netherlands</i></li> <li>4. Reaching out to the elderly: why and how, <b>Janet McElhane</b>y, <i>Northern Ontario School of Medicine, Canada</i></li> <li>5. Vaccinating pregnant women against influenza, <b>Erin Sparrow</b>, <i>(WHO)</i></li> <li>6. The benefits of a universal vaccination recommendation: the US case, <b>Litjen Tan</b>, <i>Immunization Action Coalition, USA</i></li> </ol>
18:00-19:30	<p><b>SATELLITE SYMPOSIUM</b> <i>organized by MUGAS Foundation</i></p> <p><b>NEXT GENERATION INFLUENZA VACCINES: THE FUTURE OF INFLUENZA IMMUNIZATION</b> <span style="float: right;">OMEGA</span></p> <p>■ <b>CHAIR: Ab Osterhaus</b>, <i>ESWI chair and MUGAS co-founder</i></p> <ol style="list-style-type: none"> <li>1. The need for improved influenza vaccines and adjuvants, <b>Ab Osterhaus</b>, <i>ESWI chair and MUGAS co-founder</i></li> <li>2. Molecular basis of strain variation, <b>Ron Fouchier</b>, <i>Erasmus MC Rotterdam, The Netherlands</i></li> <li>3. Pre-emptive vaccine updates and immunity management, <b>Derek Smith</b>, <i>Cambridge University, UK</i></li> <li>4. Mammalian Cell Culture and the Evolution of the Influenza Vaccine System, <b>Ethan C. Settembre</b>, <i>Seqirus, Cambridge, MA, USA</i></li> <li>5. The plant-based Proflicia™ technology, a rapid and efficient platform for the production of influenza VLP vaccines, <b>Nathalie Charland</b>, <i>Senior Director, Scientific &amp; Medical Affairs for Medicago</i></li> <li>6. Influenza adjuvanted surface low-dose Grippol® Quadrivalent vaccine immunogenicity, safety and efficacy, <b>Marina Abramova</b>, <i>Vice President, NPO Petrovax Pharm</i></li> <li>7. The revolution in influenza vaccine manufacturing: The B.E.S.T. platform used to produce Flublok®, <b>Manon Cox</b>, <i>President and CEO, Protein Sciences</i></li> </ol>
20:00-22:00	FAREWELL DINNER <span style="float: right;">LATVIA SOCIETY HOUSE</span>

## WEDNESDAY 13 SEPTEMBER 2017

08:00-09:15	<b>PL04 YOUNG SCIENTISTS PLENARY SESSION</b> <span style="float: right;">OMEGA</span>
	<ul style="list-style-type: none"> <li>▪ <b>CHAIR: Ed Hutchinson</b>, <i>University of Glasgow, UK</i></li> <li>▪ <b>CO-CHAIR: Claude Hannoun</b>, <i>Institut Pasteur Paris, France</i></li> </ul> <p><b>speakers:</b></p> <ol style="list-style-type: none"> <li>1. <b>Debby van Riel</b>, <i>ESWI Best Body of Work award winner 2017</i></li> <li>2. <b>Matthew S. Miller</b>, <i>Best Oral Presentation ESWI 2014</i></li> <li>3. <b>Steven F. Baker</b>, <i>Best Poster Presentation ESWI 2014</i></li> <li>4. <b>Karen Laurie</b>, <i>Award Winner Orthomyxovirus Research Conference 2015</i></li> <li>5. <b>Jason Long</b>, <i>Award Winner Orthomyxovirus Research Conference 2015</i></li> </ol>
09:15-10:00	COFFEE BREAK
09:30-10:00	<b>POSTER SESSION 3 Selection and introduction by by Prof. Gülsah Gabriel</b> <span style="float: right;">OMEGA</span>
10:00-11:45	<b>SPI7 INFLUENZA PREVENTION IN DEVELOPING COUNTRIES: A GLOBAL RESPONSIBILITY</b> <span style="float: right;">BETA</span>
	<ul style="list-style-type: none"> <li>▪ <b>CHAIR: Malik Peiris</b>, <i>University of Hong Kong</i></li> </ul> <ol style="list-style-type: none"> <li>1. How to protect mother and child, <b>Abdullah Brooks</b>, <i>Infectious Diseases Unit at Kamalapur Field Site, Bangladesh</i></li> <li>2. Global access to influenza vaccines for LMIC - challenges and opportunities, <b>Niteen Wairagkar</b>, <i>Bill&amp;Melinda Gates Foundation</i></li> <li>3. Logistical challenges in low income countries, <b>Mark McCaul</b>, <i>Supply Chain Officer at Médecins Sans Frontières</i></li> <li>4. Can we prevent severe outcomes through influenza vaccination? <b>Cheryl Cohen</b>, <i>National Institute for Communicable Diseases, RSA</i></li> </ol>
11:45-12:15	COFFEE BREAK
12:15-13:45	<b>PL05 PLENARY SESSION - LATE BREAKERS</b> <span style="float: right;">OMEGA</span>
	<ul style="list-style-type: none"> <li>▪ <b>CHAIR: Sylvie van der Werf</b>, <i>Institut Pasteur Paris, France</i></li> <li>▪ <b>CO-CHAIR: Susanne Herold</b>, <i>University of Giessen, Germany</i></li> </ul> <ol style="list-style-type: none"> <li>1. Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza in Otherwise Healthy Adolescents and Adults with Seasonal Influenza, <b>Frederick Hayden</b>, <i>University of Virginia School of Medicine, Charlottesville, Virginia, USA</i></li> <li>2. The OPAL Trial: A Placebo-controlled Trial Studying Pimodivir (Formerly JNJ-63623872 or VX-787) plus Oseltamivir vs. Placebo plus Oseltamivir in Adult and Elderly Hospitalized Patients with Influenza A Infection, <b>Brian O'Neil</b>, <i>Wayne State University School of Medicine, United States of America</i></li> <li>3. Targeting the pro-viral host factor, focal adhesion kinase (FAK), limits influenza A virus infections and NFkB regulated pro-inflammatory responses in vivo and in vitro, <b>Silke Bergmann</b>, <i>Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America</i></li> <li>4. Efficacy and Safety of Oseltamavir in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials, <b>Arnold S Monto</b>, <i>University of Michigan School of Public Health, United States of America</i></li> </ol>
	<b>« CLOSING CEREMONY</b> <span style="float: right;">OMEGA</span>
13:45-14:30	LUNCH